Skip to content

Turmeric Anti-Inflammatory and Cell-Damage Trial

Turmeric Anti-Inflammatory and Cell-Damage Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02815475
Acronym
TACT
Enrollment
90
Registered
2016-06-28
Start date
2016-03-31
Completion date
2016-08-31
Last updated
2016-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adults

Brief summary

This trial will be conducted for the BBC. The aim of the project is to assess if consuming the spice turmeric every other day, in the amount consumed in a curry, can reduce cell damage and inflammation. The results of the project will be used to inform the TV program Trust Me I'm a Doctor.

Detailed description

100 volunteers will be recruited for a 6 week intervention. The study group will be divided into 3 arms, each with approximately. 33 participants; one arm will receive a placebo capsule, one arm will receive a capsule with 400mg of curcumin (corresponding to two teaspoons of turmeric powder). These treatments are done double-blind. A third arm is 'open label', these volunteers will receive a bag with at least 135g turmeric and be asked to add two teaspoon to their food. Participants will be asked to supplement their diet with turmeric (powder, capsule or placebo) every other day for six weeks. Participants will be asked to attend the NU-Food research facility on 3 occasions. The first will be a screening session where participants will be given the option to discuss the project with a researcher. Participants will complete a screening questionnaire and sign an informed consent form. On the next visit, participants will arrive at the research facility at a pre-arranged time and firstly have their height and weight measured. Participants will then give 10ml of blood via venepuncture and asked to provide a 10ml spot urine sample. After this participants will be randomly allocated a treatment group (placebo, turmeric capsule or turmeric powder) and given instructions on dosage. After a 6 week treatment period, participants will return to the research facility, have their height and weight measured then give a second 10ml venous blood sample and provide a final spot urine sample. Each visit will take around 20 minutes. The main outcomes of the trial are oxidative stress and inflammation tests which will be conducted by PB bioscience and an assessment of DNA methylation by University College London. Proteomics analysis will be conducted on Urine samples.

Interventions

DIETARY_SUPPLEMENTPlacebo comparator
DIETARY_SUPPLEMENTCurcumin
DIETARY_SUPPLEMENTTurmeric powder

Sponsors

British Broadcasting Corporation
CollaboratorINDUSTRY
University College, London
CollaboratorOTHER
University of Leeds
CollaboratorOTHER
PB Biosystems Ltd
CollaboratorUNKNOWN
Newcastle University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Aged 18 years and over * No pre-existing medical conditions * not currently taking prescribed drugs or over the counter supplements * Male and female

Exclusion criteria

* Any pre-existing medical condition * Taking prescribed drugs or over the counter supplements * Aged 17 years or under * BMI \> 40mg/m2 * BP \> 160/120

Design outcomes

Primary

MeasureTime frame
Change from baseline DNA methylation analyses based on the Illumina EPIC arrayBaseline and 6 weeks post dose
Change from baseline oxidative stress determination using whole-blood chemiluminescence assaysBaseline and 6 weeks post dose

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026